Diabetes mellitus affects millions worldwide, causing a range of chronic complications that span multiple organ systems. Among these complications, necrobiosis lipoidica and diabetic retinopathy represent two distinct but interconnected manifestations of microvascular damage. While necrobiosis lipoidica primarily affects the skin, diabetic retinopathy threatens vision and can lead to blindness if left untreated. Recognizing the shared pathogenic mechanisms between these conditions is critical for comprehensive diabetes management. This article explores the relationship between necrobiosis lipoidica and diabetic retinopathy, focusing on pathophysiology, clinical implications, and integrated treatment strategies.

What Is Necrobiosis Lipoidica?

Necrobiosis lipoidica (NL) is a chronic, degenerative skin disease most commonly associated with diabetes mellitus, although it can occur in nondiabetic individuals. It typically presents as well-defined, shiny, reddish-brown or yellow-orange plaques with a characteristic waxy appearance and an atrophic center. Lesions are most frequently located on the anterior shins, though they may appear on the arms, trunk, or face. The condition is more common in women and usually begins between the ages of 20 and 40.

Histopathologically, necrobiosis lipoidica is characterized by palisading granulomas, collagen degeneration (necrobiosis), and vascular changes including endothelial swelling and thickening of vessel walls. These findings reflect a chronic inflammatory response driven by immune complexes, abnormal collagen metabolism, and microangiopathy. Up to 65% of patients with necrobiosis lipoidica have diabetes, and the skin lesions often precede the diagnosis of diabetes by several years.

The exact prevalence of NL in diabetic patients is low, estimated between 0.3% and 1.2%. However, its presence carries clinical significance as it may indicate a higher risk of other diabetic microvascular complications. The condition runs a chronic, slowly progressive course with spontaneous remission occurring in only about 20% of cases. Treatment is often challenging and includes topical corticosteroids, intralesional injections, phototherapy, and systemic immunosuppressants in severe cases.

What Is Diabetic Retinopathy?

Diabetic retinopathy (DR) is one of the most common microvascular complications of diabetes and the leading cause of preventable blindness among working-age adults in developed countries. It affects the retina, the light-sensitive tissue at the back of the eye. Chronic hyperglycemia damages retinal capillaries, leading to increased vascular permeability, capillary occlusion, and tissue ischemia.

Diabetic retinopathy is broadly classified into two stages: non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). In NPDR, early changes include microaneurysms, dot-and-blot hemorrhages, hard exudates, and cotton-wool spots. As the disease advances, capillary closure leads to retinal ischemia, triggering the release of vascular endothelial growth factor (VEGF). This drives the formation of new, fragile blood vessels in PDR, which can hemorrhage into the vitreous cavity, cause tractional retinal detachment, and result in severe vision loss. Diabetic macular edema (DME), a swelling of the macula due to fluid accumulation, can occur at any stage and is a major cause of visual impairment.

The prevalence of diabetic retinopathy increases with diabetes duration. Approximately 60% of patients with type 2 diabetes and nearly all patients with type 1 diabetes will develop some degree of retinopathy after 20 years of disease. Regular screening through dilated fundus examination or retinal photography is essential to detect early changes and institute timely treatment.

The Biological Connection: Shared Microvascular Damage

Both necrobiosis lipoidica and diabetic retinopathy originate from the same underlying pathological process: microangiopathy induced by chronic hyperglycemia. High blood glucose levels trigger a cascade of biochemical abnormalities, including increased advanced glycation end products (AGEs), activation of protein kinase C, oxidative stress, and chronic low-grade inflammation. These factors collectively damage endothelial cells, smooth muscle cells, and pericytes in small blood vessels throughout the body.

In the skin, repeated microvascular injury leads to the characteristic collagen degeneration and granuloma formation seen in necrobiosis lipoidica. In the retina, pericyte loss and endothelial cell dysfunction result in capillary basement membrane thickening, microaneurysm formation, and breakdown of the blood-retinal barrier. The parallel between these two conditions is striking: both involve progressive vascular occlusion, tissue ischemia, and an inflammatory response that perpetuates tissue damage.

Epidemiological Evidence Linking the Conditions

Several studies have investigated the association between necrobiosis lipoidica and diabetic retinopathy. A landmark prospective study published in the British Journal of Dermatology found that patients with diabetes who also had necrobiosis lipoidica had a significantly higher prevalence of proliferative diabetic retinopathy compared to diabetic patients without skin involvement. The odds of having severe retinopathy were approximately 2.5 times greater in the NL group. Other research has demonstrated that NL is an independent risk factor for advanced diabetic eye disease, even after adjusting for diabetes duration and glycemic control.

Furthermore, necrobiosis lipoidica often appears years before clinical retinopathy becomes evident. This temporal relationship suggests that the presence of NL may serve as a warning sign, prompting earlier and more rigorous ophthalmological screening. Data from longitudinal cohorts indicate that the cumulative incidence of diabetic retinopathy over 10 years is markedly higher among patients with NL than among those without it.

Histopathological Similarities

Histological examination of tissue from necrobiosis lipoidica lesions reveals vascular changes that mirror those seen in the retina. In both conditions, there is thickening of the capillary basement membrane, endothelial cell swelling, and deposition of hyaline material. Immunohistochemical studies have identified similar patterns of VEGF expression and inflammatory cell infiltration in skin biopsies from NL patients and in retinal specimens from DR patients. These shared histopathological features underscore the systemic nature of diabetic microvascular disease.

Additionally, both conditions exhibit impaired wound healing and a tendency toward tissue atrophy. In the skin, necrobiosis lipoidica leads to dermal thinning and ulceration. In the retina, ischemia and hypoxia result in the formation of cotton-wool spots (nerve fiber layer infarcts) and eventually, neovascularization. The common thread is a failure of normal repair mechanisms due to sustained metabolic insult.

Clinical Significance: Why the Connection Matters

Recognizing the link between necrobiosis lipoidica and diabetic retinopathy has important practical implications for patient care. First, it enables risk stratification. A diabetic patient presenting with characteristic plaques on the shins should be considered at elevated risk for retinopathy, even if their blood glucose levels appear well controlled. Conversely, patients with established retinopathy may benefit from dermatological evaluation for early signs of microvascular damage in the skin.

Second, the presence of necrobiosis lipoidica can motivate both patients and healthcare providers to intensify diabetes management. Evidence of skin involvement serves as a visible reminder of systemic disease activity, potentially improving adherence to lifestyle modifications and medication regimens. Studies have shown that patients who are aware of their increased complication risk are more likely to engage in regular self-monitoring and follow-up appointments.

Third, understanding the shared pathophysiology supports the use of systemic therapies that target common pathways. For example, drugs that inhibit the renin-angiotensin system (ACE inhibitors or ARBs) not only slow the progression of diabetic nephropathy but also have beneficial effects on retinal and dermal microcirculation. Similarly, fenofibrate, a peroxisome proliferator-activated receptor agonist, has been shown to reduce the progression of diabetic retinopathy and may also have positive effects on skin microangiopathy.

Screening Recommendations

Current guidelines from the American Diabetes Association recommend that all patients with type 2 diabetes receive a dilated eye examination at the time of diagnosis and annually thereafter. For patients with type 1 diabetes, initial screening should occur within five years of diagnosis, followed by yearly exams. However, these recommendations do not specifically address patients who also have necrobiosis lipoidica.

Given the heightened risk, it is reasonable to perform more frequent retinal screening in patients with NL, perhaps every six months. Additionally, any patient with NL who reports new visual symptoms—such as floaters, blurry vision, or dark spots—should undergo urgent ophthalmological evaluation. Implementation of telemedicine-based retinal imaging programs can facilitate access to screening, especially for patients in rural or underserved areas.

Management and Treatment Strategies

Integrated care is essential for patients with both necrobiosis lipoidica and diabetic retinopathy. The cornerstone of management remains optimal glycemic control. The landmark Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS) demonstrated that intensive glucose lowering reduces the incidence and progression of diabetic retinopathy. Although similar large-scale trials have not been conducted specifically for NL, observational data suggest that good metabolic control may slow the development of new skin lesions and reduce the risk of ulceration.

In addition to glucose management, blood pressure and lipid control are critically important. Hypertension is a well-established risk factor for both retinopathy and NL progression. Targeting a blood pressure below 130/80 mmHg and achieving LDL cholesterol goals can mitigate microvascular damage. Statins and fenofibrate have shown particular promise in reducing the need for laser treatment in diabetic retinopathy and may also improve dermal microcirculation.

Dermatological Interventions for Necrobiosis Lipoidica

Topical and intralesional corticosteroids are first-line treatments for necrobiosis lipoidica, especially for early, active lesions that are erythematous or enlarging. Tacrolimus ointment and other calcineurin inhibitors can be effective alternatives for long-term management, particularly when atrophy or telangiectasias are present. Phototherapy with narrowband UVB or PUVA is reserved for extensive or refractory cases. Emerging evidence supports the use of biologics such as adalimumab or tumor necrosis factor inhibitors in severe, treatment-resistant NL.

Surgical options are generally avoided due to poor wound healing and risk of ulceration. However, if ulceration does occur, advanced wound care techniques—including negative pressure wound therapy, skin grafts, and growth factor applications—may be employed. All patients with NL should be educated on proper skin hygiene, avoidance of trauma, and the importance of protective footwear.

Ophthalmological Interventions for Diabetic Retinopathy

Management of diabetic retinopathy depends on the stage and presence of macular edema. For mild to moderate NPDR without DME, intensive medical management and regular follow-up are usually sufficient. For severe NPDR and PDR, laser photocoagulation (panretinal photocoagulation) remains a mainstay to reduce neovascularization and prevent vision loss. Anti-VEGF injections (e.g., ranibizumab, aflibercept, bevacizumab) have revolutionized the treatment of both DME and PDR, offering improved visual outcomes and fewer side effects compared to laser alone.

In advanced cases with vitreous hemorrhage or tractional retinal detachment, vitrectomy surgery may be necessary. Long-term follow-up is essential, as diabetic retinopathy is a chronic, progressive condition that requires ongoing management even after successful treatment.

Prognosis and Patient Outcomes

The prognosis for patients with necrobiosis lipoidica and diabetic retinopathy is variable. Necrobiosis lipoidica tends to persist for many years, with only a minority of lesions resolving spontaneously. Ulceration occurs in up to 35% of cases and can be complicated by secondary infection or squamous cell carcinoma arising within chronic ulcers. Diabetic retinopathy, if detected early and treated appropriately, can often be stabilized. However, once proliferative changes develop, the risk of severe vision loss remains significant.

The presence of both conditions signals more aggressive systemic microvascular disease. Patients should be counseled about the importance of comprehensive risk factor management and regular follow-up with an endocrinologist, dermatologist, and ophthalmologist. Multidisciplinary clinics that integrate these specialties can improve coordination of care and patient outcomes.

Future Directions and Research Needs

Despite the recognized link between necrobiosis lipoidica and diabetic retinopathy, many gaps in knowledge remain. Prospective studies that systematically assess retinal status in a large cohort of NL patients are needed to quantify the exact risk and to identify predictive biomarkers. Advances in imaging—such as optical coherence tomography angiography (OCTA) in ophthalmology and high-frequency ultrasound or reflectance confocal microscopy in dermatology—may allow earlier detection of microvascular changes in both the skin and retina.

Furthermore, the development of therapies that target shared pathogenic pathways could benefit both conditions. For example, inhibitors of advanced glycation end products, angiogenesis, and inflammation are being investigated and may have dual efficacy. Personalized medicine approaches, guided by genetic profiling and biomarkers, may eventually enable risk prediction and tailored treatment strategies for each patient.

Conclusion: A Call for Integrated Care

The connection between necrobiosis lipoidica and diabetic retinopathy is a powerful illustration of how diabetes microangiopathy manifests across different organ systems. For clinicians, awareness of this association can enhance early detection, improve risk stratification, and guide comprehensive management. For patients, understanding the link reinforces the importance of rigorous metabolic control and regular screening for both skin and eye complications. As the evidence base continues to grow, multidisciplinary collaboration and patient-centered care remain the cornerstones of successful outcomes in diabetes management.

Key Takeaways

  • Necrobiosis lipoidica and diabetic retinopathy share a common pathogenic basis: microvascular damage from chronic hyperglycemia.
  • The presence of necrobiosis lipoidica in a diabetic patient indicates increased risk for proliferative retinopathy and vice versa.
  • Intensive glycemic, blood pressure, and lipid control are foundational for preventing or slowing both conditions.
  • Regular dilated eye exams should be performed at least annually, with more frequent screening recommended for patients with necrobiosis lipoidica.
  • Coordinated care among endocrinology, dermatology, and ophthalmology optimizes outcomes and quality of life.

References and further reading: